ADHD in the UAE: A Third Screen Positive, Almost None Are Diagnosed

The Screening Number That Should Stop You

In 2023, a national cross-sectional study set out to do something that had barely been attempted in the United Arab Emirates: count adult ADHD. It surveyed young adults across the country using the Adult ADHD Self-Report Scale — the standard 18-item screening questionnaire built on DSM symptom criteria — and the result was startling. Roughly 34.7% of the young adults screened positive for probable ADHD, with women reporting symptoms at notably higher rates than men (38.4% versus 26.5%) (Al-Yateem et al., 2023). Almost none of them had ever been formally diagnosed.

Read that carefully, because the precise wording is the whole point. In the UAE, a national study found roughly a third of young adults screen positive for probable ADHD — and almost none of them have ever been diagnosed: here the gap isn't how common it is, it's whether anyone is looking. That is the thesis of this entire piece, and everything below is the evidence and the texture behind it.

First, the fence that has to stay up the whole way through. That 34.7% is a screening figure, not a diagnosed-prevalence rate. Screening positive on a self-report scale means a person reported enough symptoms to merit a full assessment — nothing more. A diagnosis is a different and higher bar: a clinician interviews, observes, rules out other explanations, and confirms that the symptoms have been present since childhood and genuinely impair daily life. Self-report screens deliberately cast a wide net, and that net catches people who are stressed, anxious, sleep-deprived, or simply going through a hard year, not only people with ADHD. So the honest sentence is never "a third of young adults have ADHD." It is: about a third screened positive for probable ADHD, and the system did almost nothing with that signal. They were screened, not seen.

Now the children, where the UAE actually has older data. A multi-emirate study sampling school children aged 5–16 across Dubai, Al Ain and Ras Al-Khaimah — using the Conners parent and teacher scales to span urban, semi-urban and rural populations — put ADHD at about 4.1% by parent report and 3.4% by teacher report (Eapen et al., 2009). A smaller study using structured teacher interviews with 200 school-age children landed much higher, at about 12.5% (Khamis, 2011). As with everywhere in the region, the spread between those two numbers is mostly about method, not about how common the condition is — and both sit at or around the global childhood benchmark of roughly 5–7% (Faraone et al., 2021).

Put the two halves together and the shape of the problem appears. The childhood numbers are ordinary — the UAE is not an outlier on how many children have ADHD. The young-adult screening number is enormous — and there is essentially no adult diagnosed-prevalence figure to set against it, because the diagnostic counting of adults has barely happened. The UAE isn't unusual in how much ADHD it has. It's unusual in how little of it gets seen.

The Recognition Gap — Screened, Not Seen

Most countries with an ADHD problem have a prevalence problem you can argue about: is it 5% or 9%, are we over-diagnosing or under-diagnosing, where's the line. The UAE's distinctive problem is a layer up from that. The symptoms are clearly there in the population — a third of young adults raised their hand on a validated screen — and yet the formal recognition almost never arrives. That distance between screening positive and being diagnosed is the recognition gap, and it's worth understanding why it's so wide here.

The first reason is structural: adult ADHD pathways are nearly absent. Almost all UAE ADHD research, services, and clinical attention are oriented toward children — the healthcare system recognises and manages childhood ADHD reasonably well, but the infrastructure to catch an adult who was never assessed as a child is thin. There's no routine adult ADHD screening in primary care, no surveillance system tracking adult cases, and far fewer clinicians who specialise in adult presentations than the screening numbers would demand. An adult who screens positive has nowhere obvious to be sent.

The second reason is conceptual, and it's the one this article keeps returning to: the public, and many clinicians, conflate screening with diagnosis in both directions. On one side, a person reads "34.7%" and panics that a third of young adults "have ADHD" — over-reading a screen. On the other, the same screen gets dismissed as meaningless precisely because it isn't a diagnosis, so nobody acts on it. Both readings are wrong, and both leave the person who screened positive exactly where they started. The correct response to a positive screen is neither alarm nor dismissal — it's an assessment. When that step is missing system-wide, you get a population that is screened, not seen.

The third reason is specific to the UAE's demographics: it is one of the most expatriate-heavy populations on earth, with a large share of residents moving between countries, employers, and health systems over the course of their lives. Someone might be screened in a university health survey in the UAE, intend to follow up "later," relocate before they do, and re-enter a different system that knows nothing of the first signal. Continuity of care — the thing that turns a flagged symptom into a tracked diagnosis — is exactly what a highly mobile population struggles to maintain. The signal gets generated and then lost in transit.

None of this means the UAE is careless about mental health; in many ways its healthcare system is more organised and better-resourced than most of the region. It means the specific machinery for noticing adult ADHD — routine adult screening, an adult diagnostic pathway, and continuity across a mobile population — hasn't been built to match a need this size. The result is a country carrying a great deal of adult ADHD entirely off the books.

The System and the Access

To understand why the recognition gap persists, it helps to see how care is actually delivered. The UAE's healthcare system is largely private and insurance-driven, well-funded and well-organised by regional standards. For a family that knows what it's looking for and can pay or is insured, finding a child psychiatrist and getting a child assessed is genuinely achievable — and the data shows the system does this work. A study of healthcare utilisation among UAE children diagnosed with ADHD tracked 1,301 children across more than 16,000 clinical visits over four years, and found, unsurprisingly, that children with more comorbidities used more services — language and speech disorders, intellectual disability, and autism spectrum conditions were the most common companions (Almai & Salpekar, 2023). That's a system identifying and managing childhood ADHD more or less as designed.

But notice what that study is, and what it isn't. It's a portrait of children who already reached a clinic and got diagnosed. It says nothing about the adults who never did, or the children whose quieter, inattentive presentation never triggered a referral in the first place. A utilisation study can only see the people inside the system. The recognition gap is, by definition, about the people outside it — and they don't show up in the visit counts.

Access also isn't evenly distributed. Private specialist assessment can be costly, and while insurance coverage is widespread for residents, the depth of mental-health coverage varies a great deal between plans. For the large working population on more basic coverage, an adult ADHD assessment — which is time-intensive and not always covered — can sit behind a real financial barrier. The booking infrastructure exists; the question of who can afford to walk through it, and whether an adult even knows to try, is where the system thins out.

The other thin layer is informational. The clinics are here, the directories are here, the specialists are here. What barely exists is the layer that's supposed to come before the appointment: a clear, Arabic-native explanation of what ADHD actually is, what a real assessment involves, what to ask, and what your options are — written for someone living in the Emirates rather than translated from a US blog. The understanding that turns a vague private worry into a confident decision to seek assessment is the gap, the same way it is across the region.

The Medication Reality

The treatment picture in the UAE is shaped, more than anything, by how tightly ADHD stimulants are controlled. Methylphenidate — the active ingredient in Ritalin and Concerta — is internationally classified as a Schedule II controlled substance, recognised as genuinely therapeutic but carrying a high potential for misuse (BMC Medicine, 2023). The UAE regulates such medicines inside a strict national narcotics-and-psychotropics framework — they are neither freely available nor freely importable, and amphetamine-based medicines such as the Adderall family face even tighter restrictions than methylphenidate does (UAE controlled-medicines guidance). The practical effect is that access is narrower, more closely monitored, and more bureaucratically involved than in many Western countries.

That is the regulatory landscape, stated as a fact — not a workaround. This article will not tell you how to obtain, import, or get around the rules on restricted medication, and you should be wary of anything that does. Whether stimulant treatment is appropriate, which medication, at what dose, and how it is dispensed legally are decisions for a licensed UAE clinician working inside that framework. Full stop. The strictness of the law is not a reason to look for an unofficial route — it is precisely the reason the only sane path runs through a doctor.

And stimulants are not the only path. Non-stimulant medications and behavioural approaches are part of the standard picture, and they matter especially where stimulant access is constrained. A clinician may consider a non-stimulant option, parent training and behavioural therapy for a child, and structural and environmental support for an adult — alongside, or instead of, a stimulant. The honest map of how these options compare, including the things marketed as "natural," is laid out in ADHD medications and natural remedies. The bottom line for a reader in the UAE doesn't change: the regulatory reality is what it is, and your treatment is your clinician's call — never something to source on your own.

Stigma and the Adult Blind Spot

Numbers and prescriptions describe the surface. Underneath is the reason so much ADHD stays unseen even in a well-resourced system, and it's cultural before it's clinical.

Mental-health stigma is real across the region, and the UAE is no exception. In many families a psychiatric label is something to fear and hide rather than investigate — a source of worry about reputation, marriage prospects, or standing. That fear is understandable, and naming it isn't an accusation; it's a description of a real pressure that keeps people away from assessment and quiet about a diagnosis once they have one. The effect on the data is direct: under-reporting all the way down. Families hesitate, adults talk themselves out of it, cases don't reach clinics, and the country's apparent ADHD rate among adults stays near zero — which then gets read, circularly, as evidence that adult ADHD isn't really a thing here. It is the engine that keeps people screened, not seen.

Layered on top is the classic misread of the symptoms themselves. A child who can't sit still, blurts things out, and forgets the homework written on the board ten minutes ago is, to a stretched teacher, not obviously a child with a neurodevelopmental condition — he's "lazy," she's "careless." The behaviour reads as character, and it's met with discipline rather than a referral. The mechanism behind that "lazy" label — a genuine, dopamine-driven difficulty with boring, unrewarding tasks — is covered in the ADHD dopamine deficit; it is not a failure of will. And the misread compounds with age. An adult who suspects ADHD is sometimes told flatly that it's a childhood condition they've outgrown; a woman hears a particular version, that she "can't have ADHD" because the picture in many clinicians' heads is still a hyperactive young boy. The anxiety or low mood that so often travels with untreated ADHD gets named as the whole story instead — a pattern with its own literature in ADHD and its look-alikes and, for women specifically, in how ADHD shows up in women.

That is the adult blind spot, and the national screening data points straight at it. Remember that women screened higher than men in the UAE study — 38.4% to 26.5% — and yet adult women are the most under-recognised group of all, here and everywhere. The screen saw them. The system didn't. Adults diagnosed late so often describe a lifetime of being misread that the experience has become its own subject, told in full in ADHD and late diagnosis. The UAE has, in effect, run the screen and then failed to read the result — which is the most literal possible meaning of screened, not seen.

This is not, it's worth saying, a UAE-specific failing so much as a UAE-specific shape of a regional one. The neighbouring picture — a country with regional childhood studies, almost no adult data, and a system still learning to read ADHD in adults — is laid out for Egypt in ADHD in Egypt. The throughline across the region is the same: the disorder is ordinary, the counting is thin, and the adults pay for it.

Where to Get Help

If you've read this far because the description fits — you, or your child, or someone you love — here is the grounded, non-promotional version of what to do.

One thing this article will not do is hand you a self-diagnosis. If the pattern here rings true, that's a reason to seek a proper assessment — and being told once that you "can't have ADHD" is a reason to seek a second opinion, not to give up. The point of laying out the screening data, the recognition gap, and the access landscape is so that you walk into that appointment informed: knowing the difference between screening and diagnosis, knowing what a good assessment involves, and knowing that your experience is real and worth taking seriously.

Where Zalfol Fits

Everything above describes a country where the symptoms are common, the screening exists, the diagnoses don't follow, the medication is tightly held, and the practical, Arabic-native support layer barely exists. Zalfol can't change the epidemiology or the regulations, and it doesn't pretend to. What it can be is the part of the picture that's been missing: the support that's available today, in Arabic, with no waiting list — for the long stretch before assessment, alongside it, or when an appointment is simply out of reach. Here's the narrow, honest place it helps.

• The Heart is where you turn a vague "something is wrong with how I focus" into something a clinician can actually use. Log your patterns — the days that fell apart, the tasks that wouldn't start, the moods that swung — and over a few weeks you build a real record of your own experience instead of trying to reconstruct it from memory in a ten-minute appointment. That record is exactly what helps an assessment go well, especially if you're an adult or a woman walking in against the stereotype. The Heart box is not therapy. It is a log. No analysis, no advice — just an honest account you can point to. In a country that screened you and never saw you, it's how you arrive already seen.
• Goldfish is execution help that doesn't require a diagnosis to begin. You don't need a prescription or a clinic to lower the bar to a single, visible action: one task, full screen, start. On the days the workload feels impossible — diagnosed or not, medicated or not — shrinking the world down to one thing is how you keep moving without grinding yourself into shame.
• CEO Mode is the structure for an adult brain the system never caught up to. If you spent your life being told you were scattered, you may never have been handed a way to plan that fits how your attention actually works. CEO Mode is that scaffolding — turning a month of vague intentions into a few clear objectives and the small steps under them, externalised so your brain doesn't have to hold it all at once.
• Dump is the relief valve for an overloaded mind. When everything is swirling at once — and an under-supported ADHD brain in a fast, demanding place like the UAE produces a lot of swirl — you empty it all out onto the screen, unfiltered and unstructured, and let the system help sort it afterward. It's the simplest, most immediate thing here, and often the first thing that helps.

None of this is a treatment, and it isn't meant to be. Zalfol is a cognitive tool, not a medical treatment. The diagnosis belongs to a clinician and the medication belongs to the regulated system this article described. What a cognitive system can do is hold the noticing, the planning, and the starting steady — in your language, on your worst days, without an appointment — for a population that has been screened and not seen. That's the entire idea behind the way it's built. Zalfol works with the wiring. Not against it.

So take the data seriously, and take yourself seriously with it. ADHD in the UAE is not a rare condition and not a foreign import — it's a common one that the country screens for and then loses track of. The single line worth carrying out of all of this is the one the data keeps pointing back to. The Emirates already screened a third of its young adults positive — the work that's left undone isn't the counting, it's the seeing.

Frequently Asked Questions

Sources

1. Al-Yateem, N., Rossiter, R. C., Al-Shujairi, A., Saifan, A. R., Radwan, H., Awad, M., Marzbani, M., Hijazi, H., & Slewa-Younan, S. (2023). Prevalence of Undiagnosed Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in the Young Adult Population of the United Arab Emirates: A National Cross-Sectional Study. Journal of Epidemiology and Global Health, 14(1), 45–53. PMC11043292 · PMID 38079098
2. Eapen, V., Mabrouk, A. A., Zoubeidi, T., Sabri, S., Yousef, S., Al-Ketbi, J., Al-Kyomi, T., & Jakka, M. E. (2009). Epidemiological study of attention deficit hyperactivity disorder among school children in the United Arab Emirates. Hamdan Medical Journal, 2(3), 119–127.
3. Khamis, V. (2011). Attention-Deficit and Hyperactivity among School-Age United Arab Emirates Children. International Journal of Special Education, 26(3), 28–35. Full text (PDF)
4. Almai, A. M., & Salpekar, J. A. (2023). Healthcare utilisation in the United Arab Emirates for children with attention-deficit hyperactivity disorder and comorbidities. BJPsych International, 20(3), 60–63. PMC10387415
5. Alhraiwil, N. J., Ali, A., Househ, M. S., Al-Shehri, A. M., & El-Metwally, A. A. (2015). Systematic review of the epidemiology of attention deficit hyperactivity disorder in Arab countries. Neurosciences (Riyadh), 20(2), 137–144. PMC4727626
6. Faraone, S. V., et al. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. PMC8328933
7. Balancing access to ADHD medication (editorial, 2023). BMC Medicine. Notes that psychostimulants used to treat ADHD are designated Schedule II controlled substances. PMC10280932
8. United Arab Emirates — controlled medicines and narcotic/psychotropic substances guidance (narcotic and psychotropic medicines are controlled, are neither freely available nor freely importable, and require official approval). uae-embassy.org